ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,187.67
      0.00%
      US Tech 100
      17,586.00
      -0.15%
      Dow Jones
      39,056.39
      0.44%
      Brent Oil
      83.56
      0.84%
      Bitcoin
      61,133.58
      -1.93%
      Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Coherus BioSciences Inc (CHRS)

      7. Coherus BioSciences Inc (CHRS) News

      CHRS

      Coherus BioSciences (CHRS)

      Coherus BioSciences Inc
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:CHRS
      DateTimeSourceHeadlineSymbolCompany
      1:05PMiHub NewswireFeaturedElement79 Gold Corp Successfully Closes Maverick Springs Option Agreement
      05/08/20249:00AMGlobeNewswire Inc.Coherus Announces Clinical Collaboration with the Cancer Research Institute for a Novel Combination Evaluating LOQTORZI® (toripalimab-tpzi) with ENB Therapeutics' ENB-003 for the Treatment of Ovarian CancerNASDAQ:CHRSCoherus BioSciences Inc
      05/01/20244:30PMGlobeNewswire Inc.Coherus to Report First Quarter 2024 Financial Results on May 9, 2024NASDAQ:CHRSCoherus BioSciences Inc
      04/24/202410:02AMGlobeNewswire Inc.Coherus Announces Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingNASDAQ:CHRSCoherus BioSciences Inc
      04/08/20248:30AMGlobeNewswire Inc.Coherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual MeetingNASDAQ:CHRSCoherus BioSciences Inc
      03/13/20244:01PMGlobeNewswire Inc.Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business UpdateNASDAQ:CHRSCoherus BioSciences Inc
      03/05/20244:01PMGlobeNewswire Inc.Coherus to Report Fourth Quarter and Full Year 2023 Financial Results on March 13, 2024NASDAQ:CHRSCoherus BioSciences Inc
      03/04/20246:22AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:CHRSCoherus BioSciences Inc
      03/04/20241:00AMGlobeNewswire Inc.Coherus Completes Divestiture of Ophthalmology FranchiseNASDAQ:CHRSCoherus BioSciences Inc
      02/23/20245:33PMGlobeNewswire Inc.Coherus BioSciences Announces New Employment Inducement GrantsNASDAQ:CHRSCoherus BioSciences Inc
      02/22/20245:02PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CHRSCoherus BioSciences Inc
      02/22/20245:00PMEdgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:CHRSCoherus BioSciences Inc
      02/22/20244:59PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:CHRSCoherus BioSciences Inc
      02/21/20248:30AMGlobeNewswire Inc.Coherus Announces U.S. Launch of UDENYCA ONBODY™ a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqvNASDAQ:CHRSCoherus BioSciences Inc
      02/05/20248:09AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:CHRSCoherus BioSciences Inc
      02/05/20248:00AMGlobeNewswire Inc.Coherus Amends Term Loan Agreement with Pharmakon Advisors, LPNASDAQ:CHRSCoherus BioSciences Inc
      01/23/20248:05PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CHRSCoherus BioSciences Inc
      01/23/20248:04PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CHRSCoherus BioSciences Inc
      01/22/20248:01AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:CHRSCoherus BioSciences Inc
      01/22/20241:59AMDow Jones NewsSandoz to Acquire Cimerli Business from Coherus for $170 MillionNASDAQ:CHRSCoherus BioSciences Inc
      01/22/20241:15AMGlobeNewswire Inc.Coherus Announces Agreement to Divest Ophthalmology Franchise to Sandoz in $170 Million Upfront All Cash DealNASDAQ:CHRSCoherus BioSciences Inc
      01/18/20244:05PMGlobeNewswire Inc.Coherus Presents Positive Phase 2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2024 ASCO GI Cancers SymposiumNASDAQ:CHRSCoherus BioSciences Inc
      01/09/20249:41PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:CHRSCoherus BioSciences Inc
      01/09/20249:39PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:CHRSCoherus BioSciences Inc
      01/09/20247:37PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CHRSCoherus BioSciences Inc
      01/08/20246:58PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CHRSCoherus BioSciences Inc
      01/04/20245:14PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CHRSCoherus BioSciences Inc
      01/04/20245:13PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CHRSCoherus BioSciences Inc
      01/04/20248:00AMPR Newswire (US)INOVIO and Coherus Announce Clinical Collaboration to Advance Development of INO-3112 in Combination with LOQTORZI™ (toripalimab-tpzi)NASDAQ:CHRSCoherus BioSciences Inc
      01/03/20244:42PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CHRSCoherus BioSciences Inc
       Showing the most relevant articles for your search:NASDAQ:CHRS